Speculation is not evidence: antihypertensive therapy and COVID-19

Affiliations

Comment

Giovanni de Simone et al. Eur Heart J Cardiovasc Pharmacother. 2020.

. 2020 Jul 1;6(3):133-134.

doi: 10.1093/ehjcvp/pvaa021.

¹ Hypertension Research Center, Department of Advanced Biomedical Sciences, Federico II University Hospital, Naples, Italy.

No abstract available

Comment on

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
Fang L, Karakiulakis G, Roth M. Fang L, et al. Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. Lancet Respir Med. 2020. PMID: 32171062 Free PMC article. No abstract available.

1. Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M.. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003;426:450–454. - PMC - PubMed
1. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM.. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11:875–879. - PMC - PubMed
1. Chen Y, Guo Y, Pan Y, Zhao ZJ.. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun 2020;doi: 10.1016/j.bbrc.2020.02.071. - PMC - PubMed
1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS.. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020;doi:10.1007/s00134-020-05985-9. - PMC - PubMed
1. Erdos EG, Jackman HL, Brovkovych V, Tan F, Deddish PA.. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol 2002;34:1569–1576. - PubMed